Ubiquitous expression of the Pik3caH1047R mutation promotes hypoglycemia, hypoinsulinemia, and organomegaly

FASEB Journal

Volumn 29, Issue 4, 2015, Pages 1426-1434

  Kinross, Kathryn M ^a,b   Montgomery, Karen G ^a   Mangiafico, Salvatore P ^b   Hare, Lauren M ^a   Kleinschmidt, Margarete ^a   Bywater, Megan J ^a   Poulton, Ingrid J ^b   Vrahnas, Christina ^b   Henneicke, Holger ^c   Malaterre, Jordane ^a   Waring, Paul M ^b   Cullinane, Carleen ^a,b   Sims, Natalie A ^b   McArthur, Grant A ^a,b   Andrikopoulos, Sofianos ^b   Phillips, Wayne A ^a,b  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; PROTEIN KINASE B BETA; AKT2 PROTEIN, MOUSE; MUTANT PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PIK3CA PROTEIN, MOUSE; PROTEIN KINASE B;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DISEASES; EXON; GENE; GENE EXPRESSION; GENE MUTATION; GENERAL ASPECTS OF DISEASE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HYPOGLYCEMIA; HYPOINSULINEMIA; MOUSE; NONHUMAN; OBESITY; ORGAN SIZE; ORGANOMEGALY; PHOSPHATIDYLINOSITOL 3 KINASE P110ALPHA GENE; PRIORITY JOURNAL; SURVIVAL; WILD TYPE; AMINO ACID SUBSTITUTION; ANIMAL; BLOOD; DEFICIENCY; ENZYMOLOGY; FEMALE; GENE TARGETING; GENETICS; HUMAN; KNOCKOUT MOUSE; METABOLISM; MUTANT MOUSE STRAIN; MUTATION; PHYSIOLOGY; TRANSGENIC MOUSE; WEIGHT GAIN;

ANIMALIA; MUS;

AMINO ACID SUBSTITUTION; ANIMALS; FEMALE; GENE EXPRESSION; GENE KNOCK-IN TECHNIQUES; GLUCOSE; HUMANS; HYPOGLYCEMIA; INSULIN; MICE; MICE, KNOCKOUT; MICE, MUTANT STRAINS; MICE, TRANSGENIC; MUTANT PROTEINS; MUTATION; ORGAN SIZE; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; WEIGHT GAIN;

EID: 84931431380     PISSN: 08926638     EISSN: 15306860     Source Type: Journal    
DOI: 10.1096/fj.14-262782     Document Type: Article

References (45)

1. Vanhaesebroeck, B., Stephens, L., and Hawkins, P. (2012) PI3K signalling: the path to discovery and understanding. Nat. Rev. Mol. Cell Biol. 13, 195-203
2. Liu, S., Knapp, S., and Ahmed, A. A. (2014) The structural basis of PI3K cancer mutations: from mechanism to therapy. Cancer Res. 74, 641-646
3. Campbell, I. G., Russell, S. E., Choong, D. Y., Montgomery, K. G., Ciavarella, M. L., Hooi, C. S., Cristiano, B. E., Pearson, R. B., and Phillips, W. A. (2004) Mutation of the PIK3CA gene in ovarian and breast cancer. Cancer Res. 64, 7678-7681
4. Samuels, Y., Wang, Z., Bardelli, A., Silliman, N., Ptak, J., Szabo, S., Yan, H., Gazdar, A., Powell, S. M., Riggins, G. J., Willson, J. K., Markowitz, S., Kinzler, K. W., Vogelstein, B., and Velculescu, V. E. (2004) High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554
5. Hare, L. M., Phesse, T. J., Waring, P. M., Montgomery, K. G., Kinross, K. M., Mills, K., Roh, V., Heath, J. K., Ramsay, R. G., Ernst, M., and Phillips, W. A. (2014) Physiological expression of the PI3K-activating mutation Pik3ca(H1047R) combines with Apc loss to promote development of invasive intestinal adenocarcinomas in mice. Biochem. J. 458, 251-258
6. Kinross, K. M., Montgomery, K. G., Kleinschmidt, M., Waring, P., Ivetac, I., Tikoo, A., Saad, M., Hare, L., Roh, V., Mantamadiotis, T., Sheppard, K. E., Ryland, G. L., Campbell, I. G., Gorringe, K. L., Christensen, J. G., Cullinane, C., Hicks, R. J., Pearson, R. B., Johnstone, R. W., McArthur, G. A., and Phillips, W. A. (2012) An activating Pik3ca mutation coupled with Pten loss is sufficient to initiate ovarian tumorigenesis in mice. J. Clin. Invest. 122, 553-557
7. Marsh Durban, V., Deuker, M. M., Bosenberg, M. W., Phillips, W., and McMahon, M. (2013) Differential AKT dependency displayed by mouse models of BRAFV600E-initiated melanoma. J. Clin. Invest. 123, 5104-5118
8. Tikoo, A., Roh, V., Montgomery, K. G., Ivetac, I., Waring, P., Pelzer, R., Hare, L., Shackleton, M., Humbert, P., and Phillips, W. A. (2012) Physiological levels of Pik3ca(H1047R) mutation in the mouse mammary gland results in ductal hyperplasia and formation of ERα-positive tumors. PLoS ONE 7, e36924
9. Trejo, C. L., Green, S., Marsh, V., Collisson, E. A., Iezza, G., Phillips, W. A., and McMahon, M. (2013) Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression. Cancer Res. 73, 6448-6461
10. Keppler-Noreuil, K. M., Sapp, J. C., Lindhurst, M. J., Parker, V. E., Blumhorst, C., Darling, T., Tosi, L. L., Huson, S. M., Whitehouse, R. W., Jakkula, E., Grant, I., Balasubramanian, M., Chandler, K. E., Fraser, J. L., Gucev, Z., Crow, Y. J., Brennan, L. M., Clark, R., Sellars, E. A., Pena, L. D., Krishnamurty, V., Shuen, A., Braverman, N., Cunningham, M. L., Sutton, V. R., Tasic, V., Graham, J. M., Jr., Geer, J., Jr., Henderson, A., Semple, R. K., and Biesecker, L. G. (2014) Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum. Am. J. Med. Genet. A. 164, 1713-1733
11. Mirzaa, G., Conway, R., Graham, J. M., and Dobyns, W. B. (2013) PIK3CA-Related Segmental Overgrowth. In Gene Reviews (Pagon, R. A., Adam, M. P., Bird, T. D., Dolan, C. R., Fong, C.-T., and Stephens, K., eds.), pp. 1993-2014, University of Washington, Seattle, WA
12. Kurek, K. C., Luks, V. L., Ayturk, U. M., Alomari, A. I., Fishman, S. J., Spencer, S. A., Mulliken, J. B., Bowen, M. E., Yamamoto, G. L., Kozakewich, H. P. W., and Warman, M. L. (2012) Somatic mosaic activating mutations in PIK3CA cause CLOVES syndrome. Am. J. Hum. Genet. 90, 1108-1115
13. Lindhurst, M. J., Parker, V. E., Payne, F., Sapp, J. C., Rudge, S., Harris, J., Witkowski, A. M., Zhang, Q., Groeneveld, M. P., Scott, C. E., Daly, A., Huson, S. M., Tosi, L. L., Cunningham, M. L., Darling, T. N., Geer, J., Gucev, Z., Sutton, V. R., Tziotzios, C., Dixon, A. K., Helliwell, T., O'Rahilly, S., Savage, D. B., Wakelam, M. J., Barroso, I., Biesecker, L. G., and Semple, R. K. (2012) Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA. Nat. Genet. 44, 928-933
14. Rivière, J.-B., Mirzaa, G. M., O'Roak, B. J., Beddaoui, M., Alcantara, D., Conway, R. L., St-Onge, J., Schwartzentruber, J. A., Gripp, K. W., Nikkel, S. M., Worthylake, T., Sullivan, C. T., Ward, T. R., Butler, H. E., Kramer, N. A., Albrecht, B., Armour, C. M., Armstrong, L., Caluseriu, O., Cytrynbaum, C., Drolet, B. A., Innes, A. M., Lauzon, J. L., Lin, A. E., Mancini, G. M. S., Meschino, W. S., Reggin, J. D., Saggar, A. K., Lerman-Sagie, T., Uyanik, G., Weksberg, R., Zirn, B., Beaulieu, C. L., Majewski, J., Bulman, D. E., O'Driscoll, M., Shendure, J., Graham, J. M., Jr., Boycott, K. M., and Dobyns, W. B.; Finding of Rare Disease Genes (FORGE) Canada Consortium. (2012) De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes. Nat. Genet. 44, 934-940
15. Rios, J. J., Paria, N., Burns, D. K., Israel, B. A., Cornelia, R., Wise, C. A., and Ezaki, M. (2013) Somatic gain-of-function mutations in PIK3CA in patients with macrodactyly. Hum. Mol. Genet. 22, 444-451
16. Foukas, L. C., Claret, M., Pearce, W., Okkenhaug, K., Meek, S., Peskett, E., Sancho, S., Smith, A. J. H., Withers, D. J., and Vanhaesebroeck, B. (2006) Critical role for the p110α phosphoinositide-3-OH kinase in growth and metabolic regulation. Nature 441, 366-370
17. Saltiel, A. R., and Kahn, C. R. (2001) Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414, 799-806
18. Sopasakis, V. R., Liu, P., Suzuki, R., Kondo, T., Winnay, J., Tran, T. T., Asano, T., Smyth, G., Sajan, M. P., Farese, R. V., Kahn, C. R., and Zhao, J. J. (2010) Specific roles of the p110alpha isoform of phosphatidylinsositol 3-kinase in hepatic insulin signaling and metabolic regulation. Cell Metab. 11, 220-230
19. Taniguchi, C. M., Emanuelli, B., and Kahn, C. R. (2006) Critical nodes in signalling pathways: insights into insulin action. Nat. Rev. Mol. Cell Biol. 7, 85-96
20. Elstrom, R. L., Bauer, D. E., Buzzai, M., Karnauskas, R., Harris, M. H., Plas, D. R., Zhuang, H., Cinalli, R. M., Alavi, A., Rudin, C. M., and Thompson, C. B. (2004) Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 64, 3892-3899
21. DeBerardinis, R. J., Lum, J. J., Hatzivassiliou, G., and Thompson, C. B. (2008) The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab. 7, 11-20
22. Cairns, R. A., Harris, I. S., and Mak, T. W. (2011) Regulation of cancer cell metabolism. Nat. Rev. Cancer 11, 85-95
23. Ward, P. S., and Thompson, C. B. (2012) Metabolic reprogramming: a cancer hallmark even Warburg did not anticipate. Cancer Cell 21, 297-308
24. Ruzankina, Y., Pinzon-Guzman, C., Asare, A., Ong, T., Pontano, L., Cotsarelis, G., Zediak, V. P., Velez, M., Bhandoola, A., and Brown, E. J. (2007) Deletion of the developmentally essential gene ATR in adult mice leads to age-related phenotypes and stem cell loss. Cell Stem Cell 1, 113-126
25. Groszer, M., Erickson, R., Scripture-Adams, D. D., Lesche, R., Trumpp, A., Zack, J. A., Kornblum, H. I., Liu, X., and Wu, H. (2001) Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science 294, 2186-2189
26. Dummler, B., Tschopp, O., Hynx, D., Yang, Z.-Z., Dirnhofer, S., and Hemmings, B. A. (2006) Life with a single isoform of Akt: mice lacking Akt2 and Akt3 are viable but display impaired glucose homeostasis and growth deficiencies. Mol. Cell. Biol. 26, 8042-8051
27. Soriano, P. (1999) Generalized lacZ expression with the ROSA26 Cre reporter strain. Nat. Genet. 21, 70-71
28. Kinross, K. M., Brown, D. V., Kleinschmidt, M., Jackson, S., Christensen, J., Cullinane, C., Hicks, R. J., Johnstone, R. W., and McArthur, G. A. (2011) In vivo activity of combined PI3K/mTOR and MEK-inhibition in a KrasG12D; Pten deletion mouse model of ovarian cancer. Mol. Cancer Ther. 10, 1440-1449
29. Gundberg, C. M., Nieman, S. D., Abrams, S., and Rosen, H. (1998) Vitamin K status and bone health: an analysis of methods for determination of undercarboxylated osteocalcin. J. Clin. Endocrinol. Metab. 83, 3258-3266
30. Cullinane, C., Dorow, D. S., Kansara, M., Conus, N., Binns, D., Hicks, R. J., Ashman, L. K., McArthur, G. A., and Thomas, D. M. (2005) An in vivo tumor model exploiting metabolic response as a biomarker for targeted drug development. Cancer Res. 65, 9633-9636
31. Denoyer, D., Potdevin, T., Roselt, P., Neels, O. C., Kirby, L., Greguric, I., Katsifis, A., Dorow, D. S., and Hicks, R. J. (2011) Improved detection of regional melanoma metastasis using 18F-6-fluoro-N-[2-(diethylamino)ethyl] pyridine-3-carboxamide, a melanin-specific PET probe, by perilesional administration. J. Nucl. Med. 52, 115-122
32. Mangiafico, S. P., Lim, S. H., Neoh, S., Massinet, H., Joannides, C. N., Proietto, J., Andrikopoulos, S., and Fam, B. C. (2011) A primary defect in glucose production alone cannot induce glucose intolerance without defects in insulin secretion. J. Endocrinol. 210, 335-347
33. Ford-Hutchinson, A. F., Ali, Z., Lines, S. E., Hallgrímsson, B., Boyd, S. K., and Jirik, F. R. (2007) Inactivation of Pten in osteochondroprogenitor cells leads to epiphyseal growth plate abnormalities and skeletal overgrowth. J. Bone Miner. Res. 22, 1245-1259
34. Lee, N. K., Sowa, H., Hinoi, E., Ferron, M., Ahn, J. D., Confavreux, C., Dacquin, R., Mee, P. J., McKee, M. D., Jung, D. Y., Zhang, Z., Kim, J. K., Mauvais-Jarvis, F., Ducy, P., and Karsenty, G. (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130, 456-469
35. Whiteman, E. L., Cho, H., and Birnbaum, M. J. (2002) Role of Akt/protein kinase B in metabolism. Trends Endocrinol. Metab. 13, 444-451
36. Arya, V. B., Flanagan, S. E., Schober, E., Rami-Merhar, B., Ellard, S., and Hussain, K. (2014) Activating AKT2 mutation: hypoinsulinemic hypoketotic hypoglycemia. J. Clin. Endocrinol. Metab. 99, 391-394
37. Hussain, K., Challis, B., Rocha, N., Payne, F., Minic, M., Thompson, A., Daly, A., Scott, C., Harris, J., Smillie, B. J. L., Savage, D. B., Ramaswami, U., De Lonlay, P., O'Rahilly, S., Barroso, I., and Semple, R. K. (2011) An activating mutation of AKT2 and human hypoglycemia. Science 334, 474
38. Cho, H., Mu, J., Kim, J. K., Thorvaldsen, J. L., Chu, Q., Crenshaw III, E. B., Kaestner, K. H., Bartolomei, M. S., Shulman, G. I., and Birnbaum, M. J. (2001) Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB β). Science 292, 1728-1731
39. Robey, R. B., and Hay, N. (2009) Is Akt the "Warburg kinase"?- Akt-energy metabolism interactions and oncogenesis. Semin. Cancer Biol. 19, 25-31
40. Foukas, L. C., Bilanges, B., Bettedi, L., Pearce, W., Ali, K., Sancho, S., Withers, D. J., and Vanhaesebroeck, B. (2013) Longterm p110α PI3K inactivation exerts a beneficial effect on metabolism. EMBO Mol. Med. 5, 563-571
41. Smith, G. C., Ong, W. K., Rewcastle, G. W., Kendall, J. D., Han, W., and Shepherd, P. R. (2012) Effects of acutely inhibiting PI3K isoforms and mTOR on regulation of glucose metabolism in vivo. Biochem. J. 442, 161-169
42. Rodon, J., Dienstmann, R., Serra, V., and Tabernero, J. (2013) Development of PI3K inhibitors: lessons learned from early clinical trials. Nat Rev Clin Oncol 10, 143-153
43. Kolic, J., Spigelman, A. F., Plummer, G., Leung, E., Hajmrle, C., Kin, T., Shapiro, A. M., Manning Fox, J. E., and MacDonald, P. E. (2013) Distinct and opposing roles for the phosphatidylinositol 3-OH kinase catalytic subunits p110α and p110β in the regulation of insulin secretion from rodent and human beta cells. Diabetologia 56, 1339-1349
44. Kaneko, K., Ueki, K., Takahashi, N., Hashimoto, S., Okamoto, M., Awazawa, M., Okazaki, Y., Ohsugi, M., Inabe, K., Umehara, T., Yoshida, M., Kakei, M., Kitamura, T., Luo, J., Kulkarni, R. N., Kahn, C. R., Kasai, H., Cantley, L. C., and Kadowaki, T. (2010) Class IA phosphatidylinositol 3-kinase in pancreatic β cells controls insulin secretion by multiple mechanisms. Cell Metab. 12, 619-632
45. Garcia-Cao, I., Song, M. S., Hobbs, R. M., Laurent, G., Giorgi, C., de Boer, V. C. J., Anastasiou, D., Ito, K., Sasaki, A. T., Rameh, L., Carracedo, A., Vander Heiden, M. G., Cantley, L. C., Pinton, P., Haigis, M. C., and Pandolfi, P. P. (2012) Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell 149, 49-62